Quintiles Draws Curtain On Phase I India Unit As External Business Environment Gets Challenging
This article was originally published in PharmAsia News
Executive Summary
The leading CRO shutters its Phase I unit in Hyderabad inaugurated only two years ago. The decision signifies the tough regulatory challenges global companies are facing in India.
You may also be interested in...
Quintiles IPO Points To Increased Pharma Productivity And Outsourcing
Slated for May 9, this offering for the largest CRO is expected to attract a wide range of investors, including health care specialists and growth-oriented generalists. The IPO filing shows how the biopharma industry is rebounding. But the CRO’s risk-sharing projects with pharma, which gained attention in recent years, don’t seem to be that productive.
Change Of Guard At Quintiles India As Company Continues Aggressive Asia Efforts With Samsung Deal
MUMBAI - Quintiles Transnational Corp.'s India CEO Ferzaan Engineer will step down after serving the multinational contract research organization since its inception in India more than 13 years ago
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.